AU2007281677A1 - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
AU2007281677A1
AU2007281677A1 AU2007281677A AU2007281677A AU2007281677A1 AU 2007281677 A1 AU2007281677 A1 AU 2007281677A1 AU 2007281677 A AU2007281677 A AU 2007281677A AU 2007281677 A AU2007281677 A AU 2007281677A AU 2007281677 A1 AU2007281677 A1 AU 2007281677A1
Authority
AU
Australia
Prior art keywords
pyridinylmethyl
benzenedimethanamine
tetrahydro
bis
quinolinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007281677A
Other languages
English (en)
Inventor
Gary Bridger
Louis M. Pelus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2007281677A1 publication Critical patent/AU2007281677A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007281677A 2006-08-07 2007-08-07 Combination therapy Abandoned AU2007281677A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83640906P 2006-08-07 2006-08-07
US60/836,409 2006-08-07
PCT/US2007/075376 WO2008019371A1 (en) 2006-08-07 2007-08-07 Combination therapy

Publications (1)

Publication Number Publication Date
AU2007281677A1 true AU2007281677A1 (en) 2008-02-14

Family

ID=39033325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007281677A Abandoned AU2007281677A1 (en) 2006-08-07 2007-08-07 Combination therapy

Country Status (12)

Country Link
US (1) US20100178271A1 (https=)
EP (1) EP2056853A1 (https=)
JP (1) JP2010507567A (https=)
CN (1) CN101500595A (https=)
AR (1) AR062271A1 (https=)
AU (1) AU2007281677A1 (https=)
BR (1) BRPI0715393A2 (https=)
CA (1) CA2659337A1 (https=)
IL (1) IL196559A0 (https=)
MX (1) MX2009001445A (https=)
RU (1) RU2009108289A (https=)
WO (1) WO2008019371A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5389666B2 (ja) * 2007-01-09 2014-01-15 クリーブランド バイオラブス， インコーポレイテッド 造血幹細胞を増加および動員するための方法
WO2009108360A2 (en) * 2008-02-29 2009-09-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of post-radiation tumor growth
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2011119738A2 (en) 2010-03-23 2011-09-29 The Johns Hopkins University Methods of treatment using stem cell mobilizers
US8546353B2 (en) 2010-05-06 2013-10-01 Glykos Finland Oy Compounds and combinations
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
ES2370986B1 (es) * 2010-06-08 2012-11-16 Institut Quimic De Sarria Cets Nuevos inhibidores de cxcr4 como agentes anti-vih
US9155723B2 (en) 2010-06-28 2015-10-13 The General Hospital Corporation Anti-CXCR4 as a sensitizer to cancer therapeutics
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
US9682078B2 (en) 2011-03-18 2017-06-20 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
WO2012174522A1 (en) * 2011-06-16 2012-12-20 Children's Medical Center Corporation Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
JP2016516672A (ja) * 2013-02-28 2016-06-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 幹細胞を動員するための方法および組成物
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
CN110035702A (zh) 2016-10-24 2019-07-19 耶鲁大学 穿刺装置
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
EP3703714A1 (en) 2017-11-03 2020-09-09 Roemer & Heigl GmbH Extraction of stem cells from bone marrow niches
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2022101359A1 (en) 2020-11-12 2022-05-19 Roemer & Heigl Gmbh Reversible release of stem cells from bone marrow niches
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
DE69433301T2 (de) * 1993-06-08 2004-09-09 Smithkline Beecham Corp. Methoden zur erhöhung der biologischen aktivität von chemokinen
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
DE60042030D1 (de) * 1999-12-17 2009-05-28 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
PT1317451E (pt) * 2000-09-15 2006-12-29 Anormed Inc Compostos heterocíclicos que se ligam a receptores de quimioquinas
CA2419224A1 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU2002211393B2 (en) * 2000-09-29 2007-06-28 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
US6853731B1 (en) * 2000-09-30 2005-02-08 Keen Personal Technologies, Inc. Digital video recorder employing a unique ID to interlock with encrypted video programs stored on a storage device
EP1385865A4 (en) * 2001-04-03 2005-05-25 Applera Corp ISOLATED HUMAN KINASEPROTEINS, NUCLEIC ACID MOLECULES CODING FOR HUMAN KINASEPROTEINS AND THEIR USES
ES2380009T3 (es) * 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
WO2003048345A1 (en) * 2001-12-07 2003-06-12 Toolgen, Inc. Phenotypic screen of chimeric proteins
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
AU2004232361A1 (en) * 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS

Also Published As

Publication number Publication date
MX2009001445A (es) 2009-02-18
CN101500595A (zh) 2009-08-05
US20100178271A1 (en) 2010-07-15
BRPI0715393A2 (pt) 2013-06-25
EP2056853A1 (en) 2009-05-13
AR062271A1 (es) 2008-10-29
WO2008019371A1 (en) 2008-02-14
RU2009108289A (ru) 2010-09-20
IL196559A0 (en) 2011-08-01
CA2659337A1 (en) 2008-02-14
JP2010507567A (ja) 2010-03-11

Similar Documents

Publication Publication Date Title
US20100178271A1 (en) Combination Therapy
US20100003224A1 (en) Combination Therapy
KR100996378B1 (ko) 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물
US20060035829A1 (en) Chemokine combinations to mobilize progenitor/stem cells
AU2002318927A1 (en) Methods to mobilize progenitor/stem cells
EP1991221B1 (en) Methods for increasing blood flow and/or promoting tissue regeneration
HK40026817A (en) Methods to mobilize progenitor/stem cells
MX2007001802A (en) Chemokine combinations to mobilize progenitor/stem cells

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period